Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
35.83 USD | -1.05% |
|
+0.50% | -9.56% |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
06-11 | Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.56% | 2.39B | |
+26.48% | 52.73B | |
+37.49% | 39B | |
-9.23% | 38.52B | |
+28.95% | 30.38B | |
-12.26% | 26.39B | |
+10.67% | 26.08B | |
+45.20% | 14.15B | |
+32.44% | 12.6B | |
-6.06% | 11.51B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target